about
Reply to: Risk of Bias in Study of Varenicline and Cardiovascular Outcomes.Feasibility of Using a Smartwatch to Intensively Monitor Patients With Chronic Obstructive Pulmonary Disease: Prospective Cohort Study.Cardiovascular Outcomes and All-Cause Mortality in Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease (Overlap Syndrome)Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy StatementUnderdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease.End-of-Life Strategies among Patients with Advanced Chronic Obstructive Pulmonary DiseaseUsing wearables and self-management apps in patients with COPD: a qualitative studyEnd-of-life care in individuals with respiratory diseases: a population study comparing the dying experience between those with chronic obstructive pulmonary disease and lung cancerAsthma and Chronic Obstructive Pulmonary Disease Overlap in Women. Incidence and Risk FactorsReducing Chronic Obstructive Pulmonary Disease Hospital Readmissions. An Official American Thoracic Society Workshop ReportEffect of asthma exacerbation during pregnancy in women with asthma: a population-based cohort studySex differences in health services and medication use among older adults with asthmaEffectiveness and Safety of Inhaled Corticosteroids in Older Individuals with Chronic Obstructive Pulmonary Disease and/or Asthma. A Population StudyPharmacologic Management of COPD: An Official American Thoracic Society Clinical Practice GuidelinePrevalence of comorbidities and impact on pulmonary rehabilitation outcomesSocioeconomic status (SES) and 30-day hospital readmissions for chronic obstructive pulmonary (COPD) disease: A population-based cohort studyEpidemiology and health outcomes of sarcoidosis in a universal healthcare population: a cohort studyPredictors of Opioid-related Adverse Pulmonary Events among Older Adults with COPD
P50
Q53282365-08A30AC9-A7E4-40C5-9018-C70B22316BD3Q55432933-E42A21B8-2385-4412-B09B-EEE0FEA64B7FQ58100480-799EF50E-2BCB-41FE-B48A-38CE31A94020Q64041683-C7D1B530-0A35-4CB2-99BD-5FD8AEFA5962Q64933934-E69A4F28-BF17-4EA0-93C2-C58E24164D95Q89061910-300FD528-868E-4B7F-8967-31E78A8DA699Q90138199-7D497F68-7F3F-481A-AC4A-B61D82FA1337Q90168879-8696111F-9636-4959-BBF9-80D014EA2C97Q90279751-CC8EC586-3F00-46AF-B350-E6BF9FFE1C05Q91302856-540DA644-0038-4A12-8992-CFC9888673C1Q91472624-BE6F7E18-67AF-428B-BE9B-1802980D79DBQ91712276-D2F605B3-E1A1-4F2D-BE7F-4C87FD7FB749Q91828003-05116F68-6EDB-40C5-A960-85CE467531D4Q91870470-FF06F1E2-3A55-4A69-9D62-78251D6D790AQ91939703-C8515BFC-837F-4485-8910-C5957CCEC569Q92188603-4FFF7724-6BAC-4DCD-897E-4997DCAFFB55Q92481749-82455742-4325-4332-9FB8-FE2929B8D883Q94585873-5887E304-D1BE-4F01-B433-1702CA3E0668
P50
description
researcher
@en
name
Andrea S Gershon
@en
type
label
Andrea S Gershon
@en
prefLabel
Andrea S Gershon
@en
P31
P496
0000-0002-0246-594X